PTC Therapeutics secures $1 billion deal with Novartis for Huntington's disease treatment.

PTC Therapeutics has signed a major deal with Novartis for its Huntington's disease treatment PTC518, securing a $1 billion upfront payment and up to $1.9 billion in future milestones. Novartis will take over global development and commercialization post a key study, while sharing U.S. profits with PTC. PTC’s stock surged over 15% on the news, reflecting the significant financial and potential therapeutic impact of the collaboration.

December 02, 2024
16 Articles